The question of whether a common pain reliever during pregnancy is linked to autism remains unresolved—and new research suggests it might not be as dangerous as some claim. But here’s where it gets controversial: a recent review indicates there isn’t concrete evidence connecting paracetamol, also known as acetaminophen, to developmental disorders in children, despite widespread concerns. This is a topic that has sparked intense debate, especially in light of statements from high-profile figures.
A fresh analysis published in The BMJ has stated clearly that, based on existing data, there’s no definitive link between using acetaminophen while pregnant and increasing a child’s risk of autism spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD). The study, conducted by researchers from the University of Liverpool, examined nine comprehensive reviews that looked at 40 observational studies on the subject. Their conclusion was that the overall quality of evidence connecting paracetamol use during pregnancy to neurodevelopmental issues is, at best, "low"—meaning it’s not strong enough to establish a cause-and-effect relationship.
Professor Shakila Thangaratinam, the lead author of the review, emphasized that current findings should reassure healthcare providers and expectant mothers alike. “Our research shows there’s no clear evidence linking paracetamol consumption during pregnancy to autism or ADHD diagnosis in children,” she explained. “This should help medical professionals give more informed, science-backed advice to women who need this medication during pregnancy.”
The review also highlighted that many earlier studies suggesting a link may have been influenced by genetics and environmental factors shared within families—like parental mental health or lifestyle choices—rather than the medication itself. Interestingly, only two studies among those reviewed properly adjusted for these family-related factors. Once they did, the supposed connection mostly disappeared or was drastically weakened.
While scientists agree that more rigorous research is needed, the existing evidence does not support refraining from acetaminophen use during pregnancy.
Now, let’s address the controversy surrounding former President Donald Trump’s recent warning about Tylenol. Trump urged pregnant women to avoid acetaminophen, citing a supposed risk of autism—a claim that, to date, lacks scientific backing. Despite being one of the safest and most widely used medications worldwide, such assertions have created confusion and speculation. Both the World Health Organization and the European Union have dismissed Trump’s statement as unsubstantiated, with the U.S. Food and Drug Administration (FDA) clarifying that no proven causal link exists between acetaminophen use in pregnancy and developmental disorders.
Leading medical groups like the American College of Obstetricians and Gynecologists, alongside the Society for Maternal-Fetal Medicine, continue to endorse acetaminophen as a safe pain relief option for pregnant women. Nonetheless, last month, Trump and Health and Human Services Secretary Robert F. Kennedy Jr. announced that the FDA plans to update the drug’s labeling to warn of a “potential increased risk of autism.” This move has sparked intense debate, prompting the pharmaceutical company behind Tylenol, Kenvue, to call on regulators to reconsider the proposed warning. The current label advises pregnant or breastfeeding women to “consult a healthcare professional before use,” which remains consistent with current medical consensus.
In summary, while some voices continue to raise alarms, the scientific community largely maintains that there is no strong evidence linking acetaminophen during pregnancy to autism or ADHD. However, the ongoing discussion raises important questions: Should precautionary labels be mandated despite limited evidence? And how much weight should such claims carry in medical advice? Share your thoughts—do you agree that this is a case of over-cautiousness, or is there more to the story?”}
